Mosaic clade M human immunodeficiency virus type 1 (HIV-1) gag immunogens
The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies.
1. A polypeptide or protein comprising any one of the mosaic Gag polypeptide Gag M4.1-4Dmyr selected from the group consisting of SEQ ID Nos: 173-176.
2. A composition comprising at least one polypeptide or protein according to claim 1 and a carrier.
3. A method of inducing an immune response in a mammal comprising administering to said mammal an amount of at least one polypeptide or protein according to claim 1 or claim 2 sufficient to effect said induction.
4. The polypeptide according to claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 173.
5. The polypeptide according to claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 174.
6. The polypeptide according to claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 175.
7. The polypeptide according to claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 176.
8. The composition according to claim 2 comprising the four mosaic Gag M4.1-4Dmyr polypeptides comprising SEQ ID Nos: 173-176.
9. The composition according to claim 2 further comprising an adjuvant.